Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 2/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.47 |
| ▸ | MAOA | P21397 | 2/20 | 0.46 |
| ▸ | MAOB | P27338 | 2/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | AKT2 | P31751 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1919156 | 0.97 | SLC6A4 (0.45) | SLC6A4SLC6A3MAOAMAOBKDM1A | |
| SCHEMBL17680402 | 0.93 | SLC6A4 (0.42) | SLC6A4SLC6A3MAOAMAOBKDM1A | |
| SCHEMBL8478708 | 0.90 | SLC6A4 (0.53) | SLC6A4SLC6A3 | |
| SCHEMBL1492744 | 0.90 | SLC6A4 (0.48) | SLC6A4SLC6A3MAOAMAOBKDM1A | |
| Hydrochloric Acid SCHEMBL18742808 | 0.88 | SLC6A4 (0.47) | SLC6A4SLC6A3MAOAMAOBAKT2 | |
| Hydrochloric Acid SCHEMBL18662772 | 0.88 | SLC6A4 (0.52) | SLC6A4SLC6A3 | |
| SCHEMBL4125543 | 0.88 | SLC6A4 (0.57) | SLC6A4SLC6A3 | |
| SCHEMBL8155581 | 0.84 | ALDH1A1 (0.41) | SLC6A4SLC6A3MAOAMAOBKDM1A | |
| SCHEMBL1057221 | 0.84 | DRD2 (0.60) | SLC6A4SLC6A3MAOAMAOBKDM1A | |
| Hydrochloric Acid SCHEMBL4869686 | 0.83 | DRD2 (0.58) | SLC6A4SLC6A3MAOAMAOBKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2661433-B1 | INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | NOVARTIS AG (CH) | 2017-08-16 | — | — | EP | claimed |
| EP-2661433-A1 | INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | Novartis AG (CH) | 2013-11-13 | — | — | EP | claimed |
| US-20120295884-A1 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2012-11-22 | — | — | US | claimed |
| WO-2012093101-A1 | INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | NOVARTIS AG (CH) | 2012-07-12 | — | — | WO | claimed |
| US-11939320-B2 | Modulators of the integrated stress pathway | ABBVIE INC. (US) | 2024-03-26 | — | — | US | disclosed |
| CN-112409331-B | Heterocyclic derivative inhibitor, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2024-02-20 | — | — | CN | disclosed |
| WO-2023211855-A1 | KCNT1 INHIBITORS COMPRISING A THIOPHENE CORE AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2023-11-02 | — | — | WO | disclosed |
| WO-2023211855-A1 | KCNT1 INHIBITORS COMPRISING A THIOPHENE CORE AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2023-11-02 | — | — | WO | disclosed |
| EP-4265599-A1 | PYRIMIDINE CARBOXAMIDE COMPOUND AND USE THEREOF | Shanghai Meiyue Biotech Development Co., Ltd. (CN) | 2023-10-25 | — | — | EP | disclosed |
| CN-114835687-B | AhR inhibitors | 北京华森英诺生物科技有限公司 | 2023-09-05 | — | — | CN | disclosed |
| EP-3362445-B1 | OXADIAZOLE AMINE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP (KR) | 2023-01-25 | — | — | EP | disclosed |
| CN-114835687-A | AhR inhibitors | 重庆华森制药股份有限公司 | 2022-08-02 | — | — | CN | disclosed |
| EP-1382603-B1 | NITROGENOUS FUSED-RING COMPOUND HAVING PYRAZOLYL GROUP AS SUBSTITUENT AND MEDICINAL COMPOSITION THEREOF | EISAI R&D MAN CO LTD (JP) | 2008-07-23 | — | — | EP | disclosed |
| US-20080153833-A1 | Substituted pteridines for the treatment of inflammatory diseases | DOLLINGER HORST | 2008-06-26 | — | — | US | disclosed |
| CN-101208010-A | Beta-lactamylalkanoic acids for the treatment of premenstrual disorders | AZEVAN PHARMACEUTICALS INC (US) | 2008-06-25 | — | — | CN | disclosed |
| EP-1819708-A2 | SUBSTITUTED PTERIDINES FOR TREATING INFLAMMATORY DISEASES | Boehringer Ingelheim International GmbH (DE) | 2007-08-22 | — | — | EP | disclosed |
| US-7074801-B1 | Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof | EISAI CO., LTD. (JP) | 2006-07-11 | — | — | US | disclosed |
| WO-2006058868-A2 | SUBSTITUTED PTERIDINES FOR TREATING INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-08 | — | — | WO | disclosed |
| US-20060116370-A1 | Substituted pteridines for the treatment of inflammatory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-01 | — | — | US | disclosed |
| EP-1382603-A1 | NITROGENOUS FUSED−RING COMPOUND HAVING PYRAZOLYL GROUP AS SUBSTITUENT AND MEDICINAL COMPOSITION THEREOF | Eisai Co., Ltd. (JP) | 2004-01-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11939320-B2 | Modulators of the integrated stress pathway | ATF4, ATF1, DDIT3 | SLC6A4 2116/4885SLC6A3 3310/4885MAOA 3476/4885 |
| US-20120295884-A1 | Complement pathway modulators and uses thereof | C5, C3AR1, C9 | SLC6A4 2420/4885SLC6A3 4163/4885MAOA 457/4885 |
| US-20060116370-A1 | Substituted pteridines for the treatment of inflammatory diseases | LTC4S, TLR5, LTB4R2 | SLC6A4 1976/4885SLC6A3 2965/4885MAOA 1481/4885 |
| US-20080153833-A1 | Substituted pteridines for the treatment of inflammatory diseases | LTC4S, TLR5, LTB4R2 | SLC6A4 1976/4885SLC6A3 2965/4885MAOA 1481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.